Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01673386 · ClinicalTrials.gov registry record · Phase 2
A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
A Phase 2 study, sponsored by AVEO Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT01673386: Clinical Trial Phase 2 study, sponsored by AVEO Pharmaceuticals.
NCT01673386 is a Phase 2 study that was terminated before completion, run by AVEO Pharmaceuticals. The registered enrollment target is 58 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01673386, a Phase 2 study, was terminated before completion, sponsored by AVEO Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
Randomized, double-blind, 2-arm crossover study comparing tivozanib hydrochloride and sunitinib in subjects with metastatic RCC who have received no prior systemic therapy for Renal Cell Carcinoma (RCC).
Primary Outcome
The study was terminated prior to completing enrollment; due to low enrollment, no data was collected for this outcome measure.
Interventions
- DRUG Sunitinib
- DRUG Tivozanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Why NCT01673386 stopped before completion
NCT01673386 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 2 interventions - of which Sunitinib is the first listed.
NCT01673386 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01673386 about?
NCT01673386 is a clinical study titled "A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC". Randomized, double-blind, 2-arm crossover study comparing tivozanib hydrochloride and sunitinib in subjects with metastatic RCC who have received no prior systemic therapy for Renal Cell Carcinoma (RCC).
What is the current status of trial NCT01673386?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2012-07. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01673386?
The interventions under investigation include: Sunitinib (DRUG), Tivozanib (DRUG).
Who is sponsoring clinical trial NCT01673386?
This trial is sponsored by AVEO Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01673386's enrollment target sits among peer trials
58 1135th of 2000 higher than 860 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia